Regeneron Pharma (REGN) PT Lowered to $787 at RBC Capital
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $840.84 +3.78%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $787.00 (from $789.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Regeneron Announces Investor Conference Presentations
- Morgan Stanley Upgrades Suncor Energy (SU) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
